首页 › 基金 › Propel Bio Management, LLC › OVID
Propel Bio Management, LLC 对 OVID 的持仓历史
OVID THERAPEUTICS INC · 医疗保健
Propel Bio Management, LLC 在 Q3 2026 的 13F 申报中披露持有 OVID(OVID THERAPEUTICS INC)1,018,721 股,市值约 US$2.5M,约占其申报组合的 1.34%,在其申报持仓中市值排名第 24 位。 Propel Bio Management, LLC 最近 3 个申报季度中有 3 个季度披露了 OVID 持仓,最早可追溯至 Q1 2026。
最后更新: 2026-11-13 · 来源: SEC EDGAR Form 13F-HR
Propel Bio Management, LLC 对 OVID 的持仓演变
Propel Bio Management, LLC 于 Q1 2026 首次披露 OVID 持仓:921,457 股(约 US$2.0M)。 该持仓在 Q2 2026 达到峰值 1,115,538 股,市值约 US$3.0M。 在 3 次申报中,Propel Bio Management, LLC 1 次增持、1 次减持、0 次保持不变。 最近一期申报(Q3 2026)显示持股 1,018,721 股、市值约 US$2.5M,环比减持 -96,817 股。。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q1 2026 | 921.46K | $2.04M | 新进 |
| Q2 2026 | 1.12M | $3.00M | 增持 |
| Q3 2026 | 1.02M | $2.54M | 减持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 OVID 与 13F 数据
OVID(OVID THERAPEUTICS INC)属于医疗保健行业。我们追踪的基金中还有 51 只申报持有 OVID,申报仓位最大的包括:Affinity Asset Advisors, LLC (US$27.3M), ADAR1 Capital Management, LLC (US$20.0M), SILVERARC CAPITAL MANAGEMENT, LLC (US$14.8M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 OVID 的基金
- Affinity Asset Advisors, LLC 10.14M 股 · $27.29M · Q2 2026
- ADAR1 Capital Management, LLC 7.42M 股 · $19.95M · Q2 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 5.95M 股 · $14.82M · Q3 2026
- STEMPOINT CAPITAL LP 2.42M 股 · $6.50M · Q2 2026
- Ikarian Capital, LLC 2.27M 股 · $6.11M · Q2 2026
- Rosalind Advisors, Inc. 1.11M 股 · $2.98M · Q2 2026
- Sio Capital Management, LLC 1.01M 股 · $2.70M · Q2 2026
- Saturn V Capital Management LP 663.06K 股 · $1.78M · Q2 2026
- Ally Bridge Group (NY) LLC 624.56K 股 · $1.68M · Q2 2026
更多关于 Propel Bio Management, LLC
常见问题
How long has Propel Bio Management, LLC held OVID?
Propel Bio Management, LLC has disclosed OVID holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Propel Bio Management, LLC's current position in OVID?
As of Q3 2026, Propel Bio Management, LLC holds 1.02M shares of OVID (OVID THERAPEUTICS INC), valued at $2.54M, representing 1.34% of its reported portfolio and ranking #24.
Has Propel Bio Management, LLC been buying or selling OVID?
In the latest 13F filing (Q3 2026), Propel Bio Management, LLC reduced its position in OVID. The position peaked in Q2 2026 at 1.12M shares.
Which other funds hold OVID?
Other major institutional holders of OVID include Affinity Asset Advisors, LLC, ADAR1 Capital Management, LLC, SILVERARC CAPITAL MANAGEMENT, LLC, among 51 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.